Blockchain Registration Transaction Record

Oragenics Expands Phase IIa Concussion Trial to Second Site

Oragenics expands Phase IIa concussion trial to second site, dosing patients with ONP-002 intranasal therapy. Learn about this potential first-in-class treatment for mTBI and its impact on neurological care.

This news matters because concussions and mild traumatic brain injuries are a major public health concern, affecting athletes, military personnel, and accident victims. Currently, there are no FDA-approved drugs specifically for concussion treatment, leaving patients with only rest and symptom management. Oragenics' ONP-002, if successful, could become the first targeted therapy, potentially reducing recovery time and preventing long-term cognitive damage. The use of intranasal delivery also opens doors for treating other neurological conditions, making this a pivotal moment in neurology.